Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
501. |
ECCT/14/08/03 | STAND Study (Shortening Treatment by Advancing Novel Drugs) Long Title: A Phase 3 Open Label Partially Randomised Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug Sensitive Smear Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis Short Title: STAND Study (Shortening Treatment by Advancing Novel Drugs) |
Principal Investigator(s) 1. Dr Videlis Nduba 2. Dr Evans Amukoye Site(s) in Kenya 1. KEMRI-CRDR(East Nairobi) (Nairobi City county) 2. KEMRI-CRDR(West Nairobi) (Nairobi City county) |
17-08-2015 |
View |
502. |
ECCT/14/08/02 | A5288 Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE) |
Principal Investigator(s) 1. ESTHER MUMBI MAKANGA Site(s) in Kenya KEMRI/CDC CLINICAL RESEARCH CENTRE |
08-09-2014 |
View |
503. |
ECCT/14/07/01 | POST STABILIZATION VERSUS URGENT START OF HAART IN HIV-1 INFECTED CHILDREN WITH SEVERE COINFECTION |
Principal Investigator(s) 1. Grace John-Stewart Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Jaramogi Odinga Teaching and Referral Hospital (Kisumu county) 3. Kisumu East District Hospital (Kisumu county) |
21-10-2014 |
View |
504. |
ECCT/14/06/01 | ACTG -5279 Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Dr. Kevin N/A Cain Site(s) in Kenya 1. KEMRI/WRP CRS (Kericho county) 2. Moi University Clinical Research Center CRS ()12601 (Uasin Gishu county) |
30-06-2014 |
View |
505. |
ECCT/14/05/03 | Invivo II study Therapeutic efficacy of dihydroartemisinin piperaquine and artemether lumefantrine for the treatment of uncomplicated malaria in Kisumu County, Western Kenya Therapeutic efficacy of dihydroartemisinin piperaquine and artemether lumefantrine for the treatment of uncomplicated malaria in Kisumu County, Western Kenya |
Principal Investigator(s) 1. Ben Andagalu Site(s) in Kenya Kombewa Clinical Research Center |
14-07-2014 |
View |
506. |
ECCT/14/05/02 | Invivo I study In vivo and in vitro efficacy of artemisinin combination therapy in Kisumu County, Western Kenya. |
Principal Investigator(s) 1. Ben Andagalu Site(s) in Kenya Kombewa Clinical Research Center |
14-07-2014 |
View |
507. |
ECCT/14/04/01 | REACH Trial REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANAEMIA. |
Principal Investigator(s) 1. Thomas Neil Williams Site(s) in Kenya Kilifi County Hospital |
07-07-2014 |
View |
508. |
ECCT/14/03/02 | Rivaroxaban on prevention of stroke and non-central nervous system systemic embolism in patients with non valvular atrial fibrillation XANTUS-EL, Xarelto on prevention of stroke and non-central nervous system systemic embolism in patients with non valvular atrial fibrillation - a non interventional study, XA 1206 (IMPACT No. 16691) |
Principal Investigator(s) 1. Warshow Majid Mbarak Site(s) in Kenya 1. MP Shah Hospital (Nairobi City county) |
16-11-2012 |
View |
509. |
ECCT/14/03/01 | Comparison of School and Community-based Mass Drug Administration Delivery Strategies for Control of Schistosoma mansoni Infections in Western Kenyan in Areas with > 25% Prevalence |
Principal Investigator(s) 1. Mwinzi Ngina Mwinzi Site(s) in Kenya Nyanza region |
30-06-2014 |
View |
510. |
ECCT/14/02/03 | A Phase 1/2 Randomized, Double-Blind, Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus pneumoniae Whole Cell Vaccine Formulated with Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers (12-15 Months of Age) |
Principal Investigator(s) 1. Nekoye Namungu Otsyula 2. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute (KEMRI)/Walter Reed Project, Kombewa Clinical Research Center |
14-02-2014 |
View |